vs

Side-by-side financial comparison of MERCURY SYSTEMS INC (MRCY) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

MERCURY SYSTEMS INC is the larger business by last-quarter revenue ($232.9M vs $207.3M, roughly 1.1× Ultragenyx Pharmaceutical Inc.). MERCURY SYSTEMS INC runs the higher net margin — -6.5% vs -62.0%, a 55.5% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 4.4%). MERCURY SYSTEMS INC produced more free cash flow last quarter ($45.7M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 5.7%).

Mercury Systems, Inc. is a technology company serving the aerospace and defense industry. It designs, develops and manufactures open architecture computer hardware and software products, including secure embedded processing modules and subsystems, avionics mission computers and displays, rugged secure computer servers, and trusted microelectronics components, modules and subsystems.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

MRCY vs RARE — Head-to-Head

Bigger by revenue
MRCY
MRCY
1.1× larger
MRCY
$232.9M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+21.5% gap
RARE
25.9%
4.4%
MRCY
Higher net margin
MRCY
MRCY
55.5% more per $
MRCY
-6.5%
-62.0%
RARE
More free cash flow
MRCY
MRCY
$146.5M more FCF
MRCY
$45.7M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
5.7%
MRCY

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
MRCY
MRCY
RARE
RARE
Revenue
$232.9M
$207.3M
Net Profit
$-15.1M
$-128.6M
Gross Margin
26.0%
Operating Margin
-4.6%
-54.7%
Net Margin
-6.5%
-62.0%
Revenue YoY
4.4%
25.9%
Net Profit YoY
14.1%
3.5%
EPS (diluted)
$-0.26
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRCY
MRCY
RARE
RARE
Q4 25
$232.9M
$207.3M
Q3 25
$225.2M
$159.9M
Q2 25
$273.1M
$166.5M
Q1 25
$211.4M
$139.3M
Q4 24
$223.1M
$164.6M
Q3 24
$204.4M
$139.5M
Q2 24
$248.6M
$147.0M
Q1 24
$208.3M
$108.8M
Net Profit
MRCY
MRCY
RARE
RARE
Q4 25
$-15.1M
$-128.6M
Q3 25
$-12.5M
$-180.4M
Q2 25
$16.4M
$-115.0M
Q1 25
$-19.2M
$-151.1M
Q4 24
$-17.6M
$-133.2M
Q3 24
$-17.5M
$-133.5M
Q2 24
$-10.8M
$-131.6M
Q1 24
$-44.6M
$-170.7M
Gross Margin
MRCY
MRCY
RARE
RARE
Q4 25
26.0%
Q3 25
27.9%
Q2 25
31.0%
Q1 25
27.0%
Q4 24
27.3%
Q3 24
25.3%
Q2 24
29.5%
Q1 24
19.5%
Operating Margin
MRCY
MRCY
RARE
RARE
Q4 25
-4.6%
-54.7%
Q3 25
-3.8%
-106.9%
Q2 25
8.6%
-64.8%
Q1 25
-8.2%
-102.6%
Q4 24
-5.6%
-74.3%
Q3 24
-6.6%
-94.6%
Q2 24
-3.2%
-79.1%
Q1 24
-21.9%
-151.9%
Net Margin
MRCY
MRCY
RARE
RARE
Q4 25
-6.5%
-62.0%
Q3 25
-5.6%
-112.8%
Q2 25
6.0%
-69.0%
Q1 25
-9.1%
-108.5%
Q4 24
-7.9%
-80.9%
Q3 24
-8.6%
-95.7%
Q2 24
-4.3%
-89.5%
Q1 24
-21.4%
-156.8%
EPS (diluted)
MRCY
MRCY
RARE
RARE
Q4 25
$-0.26
$-1.28
Q3 25
$-0.21
$-1.81
Q2 25
$0.28
$-1.17
Q1 25
$-0.33
$-1.57
Q4 24
$-0.30
$-1.34
Q3 24
$-0.30
$-1.40
Q2 24
$-0.18
$-1.52
Q1 24
$-0.77
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRCY
MRCY
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$335.0M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.5B
$-80.0M
Total Assets
$2.5B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRCY
MRCY
RARE
RARE
Q4 25
$335.0M
$421.0M
Q3 25
$304.7M
$202.5M
Q2 25
$309.1M
$176.3M
Q1 25
$269.8M
$127.1M
Q4 24
$242.6M
$174.0M
Q3 24
$158.1M
$150.6M
Q2 24
$180.5M
$480.7M
Q1 24
$142.6M
$112.3M
Stockholders' Equity
MRCY
MRCY
RARE
RARE
Q4 25
$1.5B
$-80.0M
Q3 25
$1.5B
$9.2M
Q2 25
$1.5B
$151.3M
Q1 25
$1.5B
$144.2M
Q4 24
$1.5B
$255.0M
Q3 24
$1.5B
$346.8M
Q2 24
$1.5B
$432.4M
Q1 24
$1.5B
$140.3M
Total Assets
MRCY
MRCY
RARE
RARE
Q4 25
$2.5B
$1.5B
Q3 25
$2.5B
$1.2B
Q2 25
$2.4B
$1.3B
Q1 25
$2.4B
$1.3B
Q4 24
$2.4B
$1.5B
Q3 24
$2.4B
$1.5B
Q2 24
$2.4B
$1.6B
Q1 24
$2.4B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRCY
MRCY
RARE
RARE
Operating Cash FlowLast quarter
$51.6M
$-99.8M
Free Cash FlowOCF − Capex
$45.7M
$-100.8M
FCF MarginFCF / Revenue
19.6%
-48.6%
Capex IntensityCapex / Revenue
2.5%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$99.4M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRCY
MRCY
RARE
RARE
Q4 25
$51.6M
$-99.8M
Q3 25
$2.2M
$-91.4M
Q2 25
$38.1M
$-108.3M
Q1 25
$30.0M
$-166.5M
Q4 24
$85.5M
$-79.3M
Q3 24
$-14.7M
$-67.0M
Q2 24
$71.8M
$-77.0M
Q1 24
$-17.8M
$-190.7M
Free Cash Flow
MRCY
MRCY
RARE
RARE
Q4 25
$45.7M
$-100.8M
Q3 25
$-4.4M
$-92.7M
Q2 25
$34.0M
$-110.7M
Q1 25
$24.1M
$-167.8M
Q4 24
$81.9M
$-79.5M
Q3 24
$-20.9M
$-68.6M
Q2 24
$61.4M
$-79.0M
Q1 24
$-25.7M
$-193.9M
FCF Margin
MRCY
MRCY
RARE
RARE
Q4 25
19.6%
-48.6%
Q3 25
-1.9%
-58.0%
Q2 25
12.4%
-66.5%
Q1 25
11.4%
-120.5%
Q4 24
36.7%
-48.3%
Q3 24
-10.2%
-49.2%
Q2 24
24.7%
-53.7%
Q1 24
-12.4%
-178.2%
Capex Intensity
MRCY
MRCY
RARE
RARE
Q4 25
2.5%
0.5%
Q3 25
2.9%
0.8%
Q2 25
1.5%
1.5%
Q1 25
2.8%
1.0%
Q4 24
1.6%
0.1%
Q3 24
3.1%
1.2%
Q2 24
4.2%
1.4%
Q1 24
3.8%
3.0%
Cash Conversion
MRCY
MRCY
RARE
RARE
Q4 25
Q3 25
Q2 25
2.33×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRCY
MRCY

Airborne$84.2M36%
Components$48.7M21%
Other End Applications$36.8M16%
Electronic Warfare$27.5M12%
Other Sensor And Effector Applications$23.9M10%
Space$11.9M5%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons